UFPT Stock Analysis: Buy, Sell, or Hold?
UFPT - UFP Technologies Inc
$309.13
4.88 (1.60%)
â˛
5d:
-3.93%
30d:
+30.87%
90d:
+36.72%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When UFPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: UFPT is fairly priced but lacks strong directional signals. At 7.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: UFPT is fairly priced but lacks strong directional signals. At 7.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$360.58
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$223.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UFPT is currently trading at $309.13, which is considered slightly high relative to its 30-day fair value range of $247.95 to $319.19. From a valuation perspective, the stock is trading at a premium (Forward PE: 25.6) compared to its historical average (20.8). At these levels, the market is pricing in 7.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UFPT is in a strong uptrend. The price is currently testing key support at $300.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: UFPT scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $355.00 (+16.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UFPT is in a strong uptrend. The price is currently testing key support at $300.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: UFPT scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $355.00 (+16.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$247.95 -
$319.19
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
39.5%
All Signals
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($355.00)
- NEUTRAL: Trading at premium valuation - market expects 7.2% growth which is achievable
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$247.95 -
$319.19
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$300.08
Resistance Level
$330.51
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.63
Wall Street Target
$355.00
(+16.7%)
Revenue Growth (YoY)
15.1%
Earnings Growth (YoY)
21.3%
Profit Margin
11.5%
Valuation Premium vs History
+7.2% premium
PE vs Historical
25.6 vs 20.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.2%
(market-implied from PE analysis)
1-Year Target
$326.16
(+7%)
2-Year Target
$349.64
(+15%)
3-Year Target
$374.81
(+23%)
3-Yr Target (if PE normalizes)
(PE: 26â21)
PE COMPRESSION
$304.22
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.6, Growth: 11.8%)
$425.09
(+40%)
Base:
(SPY PE: 20.1, Growth: 11.8%)
$332.92
(+9%)
Bear:
(PE: 17.1, Growth: 11.8%)
$282.98
(-7%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (26x PE) as earnings recover.
Trailing PE: 34.00 | Current EPS (TTM): $9.20
Bull Case
$444.09
(+44%)
Analyst growth 29.0%, PE expands to 37.4
Base Case
$403.72
(+31%)
Market implied 29.0%, PE stable at 34.0
Bear Case
$212.73
(-31%)
Severe decline -20.0%, PE contracts to 28.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 12:55 AM ET
Data refreshes hourly during market hours. Next update: 1:55 AM
Data refreshes hourly during market hours. Next update: 1:55 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UFPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 35 SELL |
